Reviewer's report

Title: ROS1-ADGRG6: A case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib

Version: 1 Date: 04 Mar 2019

Reviewer: Shailesh Advani

Reviewer's report:

Abstract:

a) Spell out TKI first

b) How can authors state that "this fusion may be responsible for acquired first gen resistance" just by evaluation of one patient? It should be case series atleast to make a conclusion

Introduction:

a) Explain in brief function of these ROS1 fusions? How do they impact lung cancer prognosis?

b) Explain why this new fusion is critical? And what lacks in literature, or how despite advances prognosis still remains poor

Case Presentation:

a) Why was treatment started again back in August 2017?

b) Why was crizotinib specifically chosen for this fusion? Has it shown efficacy in previous studies?

Discussion:

a) What is the prevalence of this fusion in literature? Any previous studies in other cancers
Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

No

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Yes

Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

Not relevant to this manuscript

Quality of written English
Please indicate the quality of language in the manuscript:

Acceptable

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?
If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal